Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial

Cholangiocarcinoma is an aggressive malignancy with poor overall survival. Approximately 15% of intrahepatic cholangiocarcinomas contain FGFR alterations. Infigratinib is an oral FGFR 1–3 kinase inhibitor. Favorable results from a Phase II trial of infigratinib in advanced/metastatic FGFR-altered ch...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Future oncology (London, England) England), 2020-10, Vol.16 (30), p.2375-2384
Hauptverfasser:	Makawita, Shalini, K Abou-Alfa, Ghassan, Roychowdhury, Sameek, Sadeghi, Saeed, Borbath, Ivan, Goyal, Lipika, Cohn, Allen, Lamarca, Angela, Oh, Do-Youn, Macarulla, Teresa, T Shroff, Rachna, Howland, Michael, Li, Ai, Cho, Terry, Pande, Amit, Javle, Milind
Format:	Artikel
Sprache:	eng
Schlagworte:	Chemotherapy Cholangiocarcinoma Kinases Metastasis Mutation Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!